OXYBUTYNIN Synthesis, SAR, MCQ,Structure,Chemical Properties and Therapeutic Uses

Oxybutynin

IUPAC nomenclature

4-Diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylethanoate

 

Classification

Oxybutynin is an acetylcholine antagonist. It is a muscarinic antagonist.

 

Physiochemical Properties 

S. NO. PHYSICAL AND CHEMICAL PROPERTIES
1 Molecular weight 357.5 g/mol
2 Physical appearance Solid
3 Melting point 129-130°C
4 Solubility 50 mg/ml
5 Octanol/water partition coefficient 4.3
5 Presence of ring Cyclohexyl
6 Number of chiral centers 1
 

 

Mechanism of Action

Oxybutynin converts in it’s active metabolite N-desethyloxybutynin which competitively inhibits the postganglionic type 1,2 and 3 muscarinic receptors. This results in relaxing the bladder and hence, helps in increasing the urine capacity in the bladder. It decreases the frequent urge for urination and delays the desires for frequent voids.[1]

 

Structure Activity Relationship

  • Either R1 or R2 must be heterocyclic or carbocyclic.
  • The R3 group can be hydrogen, hydroxyl, hydroxymethyl or amide.
  • Most potent derivatives has X as an ester.
  • X can also be either oxygen or absent completely.
  • The N substituent can be quaternary ammonium salt or tertiary amine or both with different alkyl groups.
  • Maximum potency obtained when the distance between the ring substituted carbons is 2 carbon units.

 

Method of synthesis

Methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate and 4-(diethylamino)but-2-ynyl acetate reacts together in the presence of sodium methoxide to yield oxybutynin.

 

Therapeutic Uses

Oxybutynin is used for:

  • Treatment of overactive bladder
  • Reducing the frequent trips to bathroom
  • Reducing the urge for frequent voids

 

Side Effects

Side effects of Oxybutynin are:

  • Constipation
  • Nausea
  • Vomiting
  • Diarrhea
  • Headache
  • Stomach pain
  • Upset stomach
  • Unusual taste in mouth
  • Blurred vision
  • Dizziness
  • Decreased sweating
  • Dry mouth

 

MCQ

Q.1 “4-Diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylethanoate” is the IUPAC nomenclature of which drug?

a) Trihexyphenidyl

b) Propantheline

c) Oxybutynin

d) Oxazepam

Q.2 Melting point of Oxybutynin is?

a) 152-162°C

b) 129-130°C

c) 205.5°C

d) 258.5°C

Q.3 Match the following with correct classifications of the drugs.

i. Propantheline A. Benzodiazepine sedative-hypnotic
ii. Oxazepam B. Barbiturate
iii. Clozapine C. Muscarinic antagonist
iv. Thiamylal D. Benzpines

a) i-A, ii-C, iii-D, iv-B

b) i-C, ii-A, iii-D, iv-B

c) i-A, ii-B, iii-D, iv-C

d) i-C, ii-B, iii-A, iv-D

Q.4 Mechanism of action of Propantheline is based on?

a) Blocking the Muscarinic acetylcholine receptors

b) Blocking the nicotinic acetylcholine receptors

c) Agonizing the adrenergic receptors

d) Both a) and c)

Q.5   Correct sequence for True and False for the given statements related with the SAR of drug trihexyphenidyl

  • Either R1 or R2 must be heterocyclic or carbocyclic.
  • The R3 group can be hydrogen, hydroxyl, hydroxymethyl or amide..
  • X can also be either oxygen or absent completely.
  • The N substituent can be quaternary ammonium salt or tertiary amine or both with different alkyl groups.

a) TFTF

b) FTFT

c) TTTT

d)FFTF

Q.6 Steps involved in the synthesis of Oxybutynin from Methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate in the correct sequence is?

I. Reaction with 2-diisopropylaminoethanol

II. Reaction with 4-(diethylamino)but-2-ynyl acetate

III. Alkylation using methylbromide

a) I – II – III

b) I – III

c) II

d) II – I – III 

Q.7 The drug Oxybutynin is mainly used for?

a) Overactive bladder

b) Muscle spasm

c) Depression

d) Constipation 

 

For More Standard and Quality Question Bank you can Join Our Test Series Programme for GPAT, NIPER JEE, Pharmacist Recruitment Exam, Drug Inspector Recruitment Exams, PhD Entrance Exam for Pharmacy

Participate in  Free Online Test for GPAT

  Participate in Online FREE  Pharmacist  TEST: CLICK HERE 

Participate in Online FREE  Drug Inspector  TEST: CLICK HERE 

 

ANSWERS

1-c

2-b

3-b

4-a

5-c

6-c

7-a

 

 

REFERENCES 

[1] Massad CA, Kogan BA, Trigo-Rocha FE. The pharmacokinetics of intravesical and oral oxybutynin chloride. The Journal of urology. 1992 Aug 1;148(2):595-7.

Leave a Reply

Your email address will not be published. Required fields are marked *

eleven − seven =

Designed & Developed by ThemeXpert